CLAIMS OF THE APPLICATION:

1. (Original) A crystalline Form-I of Sumatriptan succinate.

2. (Currently amended) A crystalline Form-I of Sumatriptan Succinate according to claim 1 having X-ray powder diffraction pattern with peaks ~~around~~ about 12.628, 13.256, 15.412, 15.704, 16.198, 16.397, 18.107, 19.894, 20.061, 20.243, 20.582, 21.353, 22.734, 26.018 and 26.938 two-theta degrees.

3. (Original) A crystalline Form-I of Sumatriptan succinate of claim 1 which has X-ray powder diffraction pattern substantially as depicted Figure (1).

4. (Currently amended) A crystalline Form-I of Sumatriptan succinate of claim 1 which has a Differential Scanning Calorimetry thermogram, which exhibits a significant endo peak ~~around~~ about 169°C.

5. (Previously presented) A crystalline Form-I of Sumatriptan succinate of claim 1 which has a Differential Scanning Calorimetry thermogram substantially as depicted in Figure (2).

6. (Currently amended) A crystalline Form-I of Sumatriptan succinate of claim 1 having identified characteristic bands ~~around~~ about 3373, 3101, 2932, 1708, 1566, 1338, 1299, 1270, 1170, 1081, 884 and 638 cm^{-1} in Infra red spectrum.

7. (Original) A crystalline Form-I of Sumatriptan succinate of claim 1 having an Infra red spectrum substantially as depicted in Figure (3).

8. (Currently amended) A process for the preparation of ~~novel~~ crystalline Form-I of Sumatriptan succinate, which comprises;

a) treating highly pure Sumatriptan base in a ketone ~~solvents~~ solvent selected from the group consisting of acetone, methyl isobutyl ketone and methyl ethyl

ketone; or an ether solvent selected from the group consisting of tetrahydrofuran, diethyl ether, diisopropyl ether and diisobutyl ether, or an ester solvent selected from the group consisting of methyl acetate, ethyl acetate, propyl acetate and butyl acetate, or an alcoholic solvent selected from the group consisting of methanol, propanol, isopropanol, butanol, isobutanol, and mixtures thereof;

b) adding Succinic acid to the reaction mixture;

c) optionally concentrating the reaction mixture;

d) cooling the reaction mixture to a temperature of 0-35°C; and

e) filtering the isolated solid accompanied by drying the solid at a temperature of 50-100°C to afford the crystalline Form-I of Sumatriptan succinate.

9. (Original) The process as claimed in claim 8 wherein the ketone solvent of step (a) is acetone.

10. (Original) The process as claimed in claim 8 wherein the ether solvent is of step (a) is tetrahydrofuran.

11. (Original) The process as claimed in claim 8 wherein the ester solvent of step (a) is ethyl acetate.

12. (Currently amended) The process according to ~~anyone of claims~~ claim 8 ~~to 11~~ wherein the highly pure Sumatriptan is at least about 99% pure by HPLC.

13. (Original) A crystalline Form-II of Sumatriptan succinate.

14. (Currently amended) A crystalline Form-II of Sumatriptan Succinate according to claim 13 having X-ray powder diffraction pattern with peaks comprising ~~around~~ about 7.320, 18.751, 19.047, 19.966, 26.089, 29.675 and 31.474 two-theta degrees.

15. (Original) A crystalline Form-II of Sumatriptan succinate of claim 13 which has an X-ray powder diffraction pattern substantially as depicted in Figure (4).

16. (Currently amended) A crystalline Form-II of Sumatriptan succinate of claim 13 which has a Differential Scanning Calorimetry thermogram, which exhibits a significant major endo peak ~~around~~ about 168°C, and minor endo peaks ~~around~~ about 122°C and 160°C.

17. (Previously presented) A crystalline Form-II of Sumatriptan succinate of claim 13 which has a Differential Scanning Calorimetry thermogram substantially as depicted in Figure (5).

18. (Currently amended) A crystalline Form-II of Surnatriptan succinate of claim 13 having infrared characteristic bands at ~~around~~ about 3358, 3268, 2931, 1707, 1569, 1336, 1301, 1264, 1143, 1092, 884 and 639 cm^{-1} in Infra red spectrum.

19. (Original) A crystalline Form-II of Sumatriptan succinate of claim 13 having an Infrared spectrum substantially as depicted in Figure (6).

20. (Currently amended) A crystalline Form-II of Sumatriptan Succinate according to claim 13 having X-ray powder diffraction pattern with a peak ~~around~~ about 7.320 two-theta degrees and a Differential Scanning Calorimetry thermogram, which exhibits a significant major endo peak ~~around~~ about 168°C, and minor endo peaks ~~around~~ about 122°C and 160°C.

21. (Currently amended) A process for the preparation of a ~~novel~~ crystalline Form-II of Sumatriptan succinate, which comprises;

a) refluxing highly pure Sumatriptan in an aliphatic/alicyclic hydrocarbon solvent or a halogenated solvent;

b) adding Succinic acid to the reaction mixture;

c) refluxing the reaction mixture with Succinic acid;

d) cooling the reaction mixture after the step (c); and

e) isolating separated solids to afford crystalline Form-II of Sumatriptan succinate.

22. (Original) A process as claimed in claim 21 of step (a), wherein the alicyclic hydrocarbon solvent is cyclohexane.

23. (Original) A process as claimed in claim 21 wherein the halogenated solvent of step (a) is dichloromethane.

24. (Original) A process according to claim 21 wherein the highly pure Sumatriptan is at least about 99% pure by HPLC.

25. (Canceled)

26. (Canceled)

27. (Currently amended) A process for the preparation of highly pure N-Methyl-3- [2-(dimethylamino) ethyl]-1H-Indole-5 methane sulfonamide (Sumatriptan), which comprises;

~~f~~ a. dissolving crude Sumatriptan in acetone to form a clear solution;

~~g~~ b. treating the obtained clear solution with charcoal;

~~h~~ c. concentrating the clear filtered solution to about filterable volume level;

~~i~~ d. cooling the reaction mixture to a temperature of 0-30°C; and

~~j~~ e. isolating the obtained solid ~~by conventional methods~~.

28. (Original) The process according to claim 27 wherein the highly pure Sumatriptan is at least about 99% pure by HPLC.

29. (Previously presented) A composition comprising a crystalline Form I of Sumatriptan succinate as defined as in claim 1 and one of more pharmaceutically acceptable carrier.

30. (Previously presented) A composition comprising a crystalline Form II of Sumatriptan succinate as defined as in claim 13 and one of more pharmaceutically acceptable carrier.

31. (Canceled)

32. (Canceled)

33. (Canceled)

34. (Canceled)

35. (Canceled)

36. (Previously presented) A crystalline form of sumatriptan base having a purity of about 99% or higher by HPLC.

37. (Previously presented) A crystalline form of sumatriptan base according to claim 36, wherein said purity is about 99.5% or higher by HPLC.

38. (Previously presented) A crystalline form of sumatriptan base according to claim 36, wherein said purity is about 99.7% or higher by HPLC.

39. (Previously presented) A crystalline form of sumatriptan base according to claim 36, wherein said crystalline form of sumatriptan base has any unknown purity about 0.1% or less.

40. (Currently amended) A crystalline form of sumatriptan base according to claim 36, wherein said crystalline form has an X-ray powder diffraction pattern substantially the same as Figure 7.

41. (Currently amended) A crystalline form of sumatriptan base according to claim 36, wherein said crystalline ~~for~~ form has an ~~IR~~ infrared spectrum substantially the same as Figure 8.

42. (Previously presented) The crystalline Form-II of Sumatriptan succinate according to claim 14, wherein said peaks further comprise 14.707 and 22.904 two-theta degrees.

43. (Currently amended) A composition comprising the crystalline form of sumatriptan base as defined as in claim 36 and one ~~of~~ or more pharmaceutically acceptable carrier.

44. (Previously presented) A method for treating a migraine comprising administering an effective amount of the compound of claim 1.

45. (Previously presented) A method for treating a migraine comprising administering an effective amount of the compound of claim 15.

46. (Previously presented) A method for treating a migraine comprising administering an effective amount of the compound of claim 36.

47. (Previously presented) A compound of sumatriptan base prepared according to claim 27.